The Effect of Growth Hormone on Weight Gain and Pulmonary Function in Patients with Chronic Obstructive Lung Disease

Pape, Gregory S.; Friedman, Mitchell; Underwood, Louis E.; Clemmons, David R.

doi:10.1378/chest.99.6.1495

Cited by 187 publications

(72 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this regard, GH has demonstrated clear anabolic effects in such patients and is currently approved for use in HIV/AIDS-associated wasting syndrome as well as in other conditions, such as chronic renal failure and some cases of short bowel syndrome. GH has also been used in patients with COPD and malnutrition, inducing substantial weight improvement and lean body mass gain (594,595). Nonetheless, results on respiratory and limb muscle strength and exercise capacity are still controversial (587,594,596,597).…”

Section: American Thoracic Society Documentsmentioning

confidence: 99%

“…GH has also been used in patients with COPD and malnutrition, inducing substantial weight improvement and lean body mass gain (594,595). Nonetheless, results on respiratory and limb muscle strength and exercise capacity are still controversial (587,594,596,597). Therapy with GH is currently administered through subcutaneous injections of recombinant GH (0.05-0.06 mg/kg daily), several times per week, and side effects include paresthesias, arthralgias, insulin resistance-glucose intolerance, sodium retention, peripheral edema, and arterial hypertension (598).…”

Section: American Thoracic Society Documentsmentioning

confidence: 99%

See 1 more Smart Citation

An Official American Thoracic Society/European Respiratory Society Statement: Update on Limb Muscle Dysfunction in Chronic Obstructive Pulmonary Disease

Maltais¹,

Decramer²,

Casaburi³

et al. 2014

Am J Respir Crit Care Med

885

1,033

View full text Add to dashboard Cite

Section: American Thoracic Society Documentsmentioning

confidence: 99%

Section: American Thoracic Society Documentsmentioning

confidence: 99%

An Official American Thoracic Society/European Respiratory Society Statement: Update on Limb Muscle Dysfunction in Chronic Obstructive Pulmonary Disease

Maltais¹,

Decramer²,

Casaburi³

et al. 2014

Am J Respir Crit Care Med

885

1,033

View full text Add to dashboard Cite

“…Considering studies in patients with COPD, SUCHNER et al [13] reported that 1 week treatment with growth hormone in six severely underweight (o10% weight loss in the previous year) patients with COPD resulted in a positive nitrogen balance, and also in increased fat oxidation and energy expenditure and decreased glucose oxidation. No changes in body weight, muscle function or lung function were found [14]. In seven underweight (v90% of ideal body weight) patients with COPD, in an uncontrolled study design, 3 weeks of recombinant human growth hormone administration increased weight and improved nitrogen balance and maximal inspiratory pressure, with no adverse effects [15].…”

mentioning

confidence: 94%

Endocrinological disturbances in chronic obstructive pulmonary disease

Creutzberg¹,

Casaburi²

2003

Eur Respir J

View full text Add to dashboard Cite

In this overview, the available literature on endocrinological disturbances in chronic obstructive pulmonary disease (COPD) is reviewed, with stress on growth hormone/insulin-like growth factor I (IGF‐I), thyroid hormone and the anabolic steroids.In COPD, little is known about circulating growth hormone or IGF‐I concentrations. Some authors find a decrease in growth hormone or IGF‐I, others an increase. An increase of growth hormone might reflect a nonspecific response of the body to stress (for instance, hypoxaemia). Until now, only one controlled study on growth hormone supplementation has been published, which however did not reveal any functional benefits. Before growth hormone supplementation can be advised as part of the treatment in COPD, further controlled studies must be performed to investigate its functional efficacy. The prevalence of thyroid dysfunction in COPD and its role in pulmonary cachexia has not been extensively studied. So far, there is no evidence that thyroid function is consistently altered in COPD, except perhaps in a subgroup of patients with severe hypoxaemia. Further research is required to more extensively study the underlying mechanisms and consequences of disturbed thyroid function in this subgroup of COPD patients.A few studies have reported the results of anabolic steroid supplementation in chronic obstructive pulmonary disease. Although some studies have discerned that low circulating levels of testosterone are common in males with chronic obstructive pulmonary disease, little is known about the prevalence, the underlying causes or functional consequences of hypogonadism in these patients. The use of systemic glucocorticosteroids and an influence of the systemic inflammatory response have been suggested as contributing to low testosterone levels. It can be hypothesised that low anabolic hormones will reduce muscle mass and eventually result in a diminished muscle function. Further evidence is required before testosterone replacement can be recommended for males with chronic obstructive pulmonary disease.

show abstract

“…It significantly enhanced cell-mediated immunity and decreased wound infection rates and length of hospitalization in a large group of postoperative patients [22] . Some clinical trials reported that growth hormone enhanced nitrogen retention of patients with chronic obstructive lung diseases [23] , severe sepsis [24,25] and emaciated AIDS [26,27] , in addition to fasted adult volunteers. Although there are many controversies [28][29][30][31][32] , it has been confirmed that rhGH is an effective drug to accelerate protein anabolism [33] and plays a central role in metabolic intervention with a significant costeffect benefit [34] .…”

Section: Introductionmentioning

confidence: 99%

Protective effects of recombinant human growth hormone on cirrhotic rats

Chen

Wang²,

Yang³

et al. 2004

WJG

View full text Add to dashboard Cite

AIM:To investigate the effects and molecular mechanisms of recombinant human growth hormone (rhGH) on protecting liver function and alleviating portal hypertension of liver cirrhotic rats. METHODS:Liver cirrhosis of male Sprague-Dawley rats was induced by administration of thioacetamide. The rats with or without liver cirrhosis were randomly divided into four groups. Group A consisted of the normal rats was treated with normal saline (NS), group B consisted of the normal rats was treated with rhGH, group C consisted of cirrhotic rats was treated with NS, and group D consisted of cirrhotic rats was treated with rhGH. The rats of different groups were subcutaneously injected with 0.5 mL of NS or 333 ng/kg of rhGH daily for 7 d. After treatments, the following parameters were examined, including GH-binding capacity (R T ) by 125 I-hGH binding, growth hormone receptor mRNA(GHR mRNA) expression by RT-PCR, relative content of collagen (RCC) by histomorphomertry, and level of malon-dialdehyde (MDA) and superoxide dismutase (SOD) in liver tissue by thiobarbituric acid reaction and pyrogallic acid self-oxidation, respectively. Serum albumin (ALB), alanine transaminase (ALT) and portal vein pressure (PVP) were also examined.

show abstract

The Effect of Growth Hormone on Weight Gain and Pulmonary Function in Patients with Chronic Obstructive Lung Disease

Cited by 187 publications

References 26 publications

An Official American Thoracic Society/European Respiratory Society Statement: Update on Limb Muscle Dysfunction in Chronic Obstructive Pulmonary Disease

An Official American Thoracic Society/European Respiratory Society Statement: Update on Limb Muscle Dysfunction in Chronic Obstructive Pulmonary Disease

Endocrinological disturbances in chronic obstructive pulmonary disease

Protective effects of recombinant human growth hormone on cirrhotic rats

Contact Info

Product

Resources

About